Latest Breaking News On - Peter guenter - Page 8 : comparemela.com

Almirall da marcha atrás en la compra de la californiana Bioniz Therapeutics

Merck KGaA gains exclusive rights to Debiopharma's late-stage oncology asset

Debiopharm Grants a Worldwide Exclusive License to Merck KGaA, Darmstadt, Germany for the Development and Commercialization of Xevinapant

Debiopharm Grants a Worldwide Exclusive License to Merck KGaA, Darmstadt, Germany for the Development and Commercialization of Xevinapant USA - English Xevinapant is the first Inhibitor of Apoptosis Proteins antagonist with FDA Breakthrough Therapy Designation for previously untreated locally advanced squamous cell carcinoma of the head and neck, in combination with current standard of care A Phase II trial reported that xevinapant plus chemoradiotherapy reduced risk of death by 51% vs standard of care in this patient population; Phase III TrilynX study initiated in September 2020 Merck KGaA, Darmstadt, Germany gains exclusive global development and commercialization rights; Debiopharm to receive €188 million upfront and up to €710 million in milestone, as well as royalty payments

Debiopharm Grants a Worldwide Exclusive License to Merck for the Development and Commercialization of Xevinapant

Debiopharm Grants a Worldwide Exclusive License to Merck for the Development and Commercialization of Xevinapant - Xevinapant is the first Inhibitor of Apoptosis Proteins antagonist with FDA Breakthrough Therapy Designation for previously untreated locally advanced squamous cell carcinoma of the head and neck, in combination with current standard of care - A Phase II trial reported that xevinapant plus chemoradiotherapy reduced risk of death by 51% vs standard of care in this patient population; Phase III TrilynX study initiated in September 2020 - Merck gains exclusive global development and commercialization rights; Debiopharm to receive €188 million upfront and up to €710 million in milestone, as well as royalty payments

Merck KGaA, Darmstadt, Germany, Announces Leadership Change for North America and Global Innovative Medicine Franchises in Healthcare

Merck KGaA, Darmstadt, Germany, Announces Leadership Change for North America and Global Innovative Medicine Franchises in Healthcare News provided by Share this article Share this article DARMSTADT, Germany, Feb. 4, 2021 /PRNewswire/  Merck KGaA, Darmstadt, Germany, which operates its Healthcare business sector as EMD Serono in the US and Canada, today announced that Rehan Verjee has made the decision to leave his position as President of EMD Serono and Global Head of Innovative Medicine Franchises, to pursue an opportunity outside of the Company that will soon be announced.  He will be succeeded by Andrew Paterson, who is currently Senior Vice President and Head of both the Global Multiple Sclerosis (MS) Franchise and the MS business unit in the United States.